In vitro evaluation of cyanovirin-N antiviral activity, by use of lentiviral vectors pseudotyped with filovirus envelope glycoproteins.

Cyanovirin-N (CV-N) has been shown to inhibit Ebola Zaire virus (EboZV) infection, both in vitro and in vivo, through its ability to bind to oligomannoses-8/9 on the EboZV surface glycoprotein (GP). Here, we report the in vitro potency of CV-N to inhibit EboZV GP- and Marburg virus GP-pseudotyped viruses (EC50 approximately 40-60 nmol/L and approximately 6-25 nmol/L, respectively) from mediating gene transduction into HeLa cells. In addition, we provide evidence that CV-N can effectively inhibit DC-SIGN-mediated EboZV infection. Our data emphasize both the utility of GP-pseudotyped vectors in the assessment of compounds that affect cell entry by filovirus and the use of CV-N as a reagent for the probing of carbohydrate-dependent interactions at viral entry.

[1]  R. Doms,et al.  The role of DC-SIGN and DC-SIGNR in HIV and Ebola virus infection: can potential therapeutics block virus transmission and dissemination? , 2002, Expert opinion on therapeutic targets.

[2]  Mike Bray,et al.  Cyanovirin-N binds to the viral surface glycoprotein, GP1,2 and inhibits infectivity of Ebola virus. , 2003, Antiviral research.

[3]  G. Nolan,et al.  Generation of retroviral vector for clinical studies using transient transfection. , 1999, Human gene therapy.

[4]  M. Boyd,et al.  Multiple Antiviral Activities of Cyanovirin-N: Blocking of Human Immunodeficiency Virus Type 1 gp120 Interaction with CD4 and Coreceptor and Inhibition of Diverse Enveloped Viruses , 2000, Journal of Virology.

[5]  H. Feldmann,et al.  The glycoproteins of Marburg and Ebola virus and their potential roles in pathogenesis. , 1999, Archives of virology. Supplementum.

[6]  A. Gronenborn,et al.  The highly specific carbohydrate-binding protein cyanovirin-N: structure, anti-HIV/Ebola activity and possibilities for therapy. , 2005, Mini reviews in medicinal chemistry.

[7]  Á. Corbí,et al.  C-Type Lectins DC-SIGN and L-SIGN Mediate Cellular Entry by Ebola Virus in cis and in trans , 2002, Journal of Virology.

[8]  K. Gustafson,et al.  Potent Anti-Influenza Activity of Cyanovirin-N and Interactions with Viral Hemagglutinin , 2003, Antimicrobial Agents and Chemotherapy.

[9]  H. Katinger,et al.  The Broadly Neutralizing Anti-Human Immunodeficiency Virus Type 1 Antibody 2G12 Recognizes a Cluster of α1→2 Mannose Residues on the Outer Face of gp120 , 2002, Journal of Virology.

[10]  A. Gronenborn,et al.  Multisite and multivalent binding between cyanovirin-N and branched oligomannosides: calorimetric and NMR characterization. , 2002, Chemistry & biology.

[11]  A. Gronenborn,et al.  Functional homologs of cyanovirin-N amenable to mass production in prokaryotic and eukaryotic hosts. , 2002, Protein expression and purification.

[12]  D O Morgan,et al.  Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity , 1995, Journal of virology.

[13]  D. A. Sanders.  No false start for novel pseudotyped vectors. , 2002, Current opinion in biotechnology.

[14]  W. Weis,et al.  Structural Basis for Selective Recognition of Oligosaccharides by DC-SIGN and DC-SIGNR , 2001, Science.

[15]  L K Pannell,et al.  Discovery of cyanovirin-N, a novel human immunodeficiency virus-inactivating protein that binds viral surface envelope glycoprotein gp120: potential applications to microbicide development , 1997, Antimicrobial agents and chemotherapy.